Sign inCreate account

Report workspace tools

NCT00676650TERMINATEDanonymous

A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen

Sponsor

Source record

Pfizer

Phase

Source record

PHASE 3

Modality

AI-normalized

small molecule

Target

AI-normalized

Metastatic Castration-Resistant Prostate Cancer

Indication / condition

AI-normalized

Prostatic Neoplasms

Intervention

Source record

Prednisone, sunitinib, Placebo, Prednisone

Source & freshness

Source record

NCT ID

NCT00676650

Original source

ClinicalTrials.gov

Source last updated

Mar 08, 2013

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00676650

Title

A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen

Sponsor

Pfizer

Status

TERMINATED

Phase

PHASE 3

Condition raw

Prostatic Neoplasms

Condition normalized

Prostatic Neoplasms

Modality raw

Prostatic Neoplasms

Modality normalized

small molecule

Target raw

Metastatic Castration-Resistant Prostate Cancer

Target normalized

Metastatic Castration-Resistant Prostate Cancer

Interventions

Prednisone, sunitinib, Placebo, Prednisone

Public preview

Source record

This clinical trial aimed to evaluate the efficacy and safety of sunitinib combined with prednisone in patients with metastatic castration-resistant prostate cancer who had previously failed docetaxel chemotherapy. The study was terminated early due to futility, indicating that the combination did not demonstrate sufficient efficacy compared to the control.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00676650

Status

TERMINATED

Phase

PHASE 3

Sponsor

Pfizer

Executive brief

Investment-Ready Snapshot

This clinical trial aimed to evaluate the efficacy and safety of sunitinib combined with prednisone in patients with metastatic castration-resistant prostate cancer who had previously failed docetaxel chemotherapy. The study was terminated early due to futility, indicating that the combination did not demonstrate sufficient efficacy compared to the control.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 08, 2013
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00676650

Indication

Prostatic Neoplasms

Modality

small molecule

Target

Metastatic Castration-Resistant Prostate Cancer

Intervention

Prednisone, sunitinib, Placebo, Prednisone

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.